Combined therapy with arbekacin and fosfomycin for methicillin-resistant Staphylococcus aureus infections.
We examined the clinical efficacy of a combination of arbekacin and fosfomycin in the treatment of various methicillin-resistant Staphylococcus aureus (MRSA) infections. The combination of arbekacin plus fosfomycin displayed 65.4% (17/26) clinical efficacy and 65.4% (17/26) bacteriological efficacy. This combination thus appeared to be an effective regimen for the treatment of MRSA infections. However, its bacteriological efficacy against concomitant Pseudomonas aeruginosa strains was only 16.7% (1/6). In addition, in 4 episodes of superinfection involving P. aeruginosa strains developed during the combination therapy.
Kono
K
K
Second Department of Internal Medicine, Fukuoka University, School of Medicine.
Takeda
S
S
Tatara
I
I
Arakawa
K
K
Tanaka
H
H
Miyake
S
S
Minamikawa
H
H
Hoshino
H
H
Sato
M
M
Hattori
F
F
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D003982:Dibekacin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005578:Fosfomycin / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013203:Staphylococcal Infections / Q000150:complications / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects*; D015163:Superinfection / Q000188:drug therapy
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D005578:Fosfomycin; D003982:Dibekacin; C031986:arbekacin